Plain-English translation of NCT07920861 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Psoriasis research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new medication called , which is being developed to treat skin and joint inflammation conditions. The study has two main goals: first, to see how safe and well-tolerated a single injection of HB0017 is in healthy people who weigh less than average; and second, to understand how the body absorbs and processes this medication depending on where it is injected (abdomen, upper arm, or thigh).
Before any new medication can be tested in patients with actual disease, researchers need to understand how safe it is and how the body handles it in healthy people first. This early-stage study helps scientists learn the best dose and injection location before moving forward to help people with inflammatory skin and joint conditions.
You likely qualify if…
You likely don't qualify if…
You will receive a single injection of the medication (or placebo) under your skin at a location determined by your study group. The study has two parts: Part 1 tests different doses in people with lower body weight to assess safety, while Part 2 tests whether the medication works the same way when injected in different body locations (abdomen, upper arm, or thigh). You will need to attend multiple clinic visits for blood tests, physical exams, and monitoring to see how your body responds to the injection over time.
AI-generated summary from trial data · Nov 9, 2026 · Not medical advice
China